CALGARY, ALBERTA--(MARKET WIRE)--Jul 19, 2006 -- Resverlogix Corp. ("Resverlogix") (TSX:RVX.TO - News), on behalf of its subsidiary RVX Therapeutics Inc ("RVX"), is pleased to announce today the signing of a licensing agreement between RVX and Medtronic, Inc.(NYSE:MDT - News) ('Medtronic') whereby RVX would grant to Medtronic exclusive, worldwide rights to develop and commercialize its ReVas(TM) technology with drug eluting medical devices for the local, non-systemic treatment of cardiovascular diseases, in particular restenosis and stenosis.
